Product name: RAD-140
Molecular Formula: C20H16ClN5O2
Description: RAD-140 is currently under development as a product with testosterone replacement therapy capabilities which has been discovered to carry key benefits attributable to increased testosterone in healthy male subjects. Trials to date have not shown any notable negative side effects and performance and lean muscle growth capabilities are well documented in this new research compound.
||Premium Ceramic Dropper
||1 x Bottle RAD-140(30ml)
||Premium Research Chemicals
Elite Scientific Analysis:
RAD-140 (Testolone) is a selective androgen receptor modulator (SARM) currently under development by Radius Health as a product for testosterone replacement therapy capabilities to aid in the treatment of muscle wasting associated with diseases such as cancer. It was first discovered in 2010.
RAD140 has been shown to carry key benefits attributable to increased testosterone in healthy male subjects and in animal models has been shown to counter the prostate-enlargement caused by testosterone use. RAD140 stimulates the levator ani muscle in a mouse studies.
In studies in Macaca fascicularis a mean weight gain of greater than 10% in just 28 days of dosing was achieved at a dose of just 0.1 mg/kg, with a similar effect observed at the 1.0 mg/kg dosing group.
Through X-ray absorptiometry analysis no consistent effect on absolute fat mass was observed, whereas muscle showed a qualitative trend that increases with dosage. This means that RAD-140 has been shown to increase muscle mass without having a significant impact on fat deposits.
Clinical chemistry indicated the expected lowering of lipids (LDL, HDL, and triglycerides). Despite the rather dramatic increases in body weight over such a short time, there was no elevation of liver enzyme transaminase levels in any animal at any dose >2 fold over its baseline value which indicates this compound will not have adverse effects upon the liver.
RAD140 is efficacy selective because it is fully anabolic on muscle but demonstrates less than complete efficacy on the prostate and seminal vesicles and can partially antagonize the stimulation of the seminal vesicles induced by testosterone.
Overall RAD140 has excellent pharmacokinetics and is a potent anabolic in nonhuman primate. The overall preclinical profile of RAD140 is very good, and the compound has completed preclinical toxicology in both rats and monkeys. It is currently being prepared for Phase I clinical studies in patients suffering from severe weight loss due to cancer cachexia.
Trials to date have not shown any notable negative side effects and performance and lean muscle growth capabilities are well documented.
Miller C. P., Shomali M., Lyttle C.R., O'Dea L.S., Herendeen H., Gallacher K., Paquin D., Compton D.R., Sahoo B., Kerrigan S.A., Burge M.S., Nickels M., Green J.L., Katzenellenbogen J.A., Tchesnokov A., Hattersley G., Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140, ACS Medicinal Chemistry Letters, 2011, 2 (2), 124–9.
Miller C., Shomali M., Lyttle C.R., Hattersley G., A Selective Androgen Receptor Modulator (RAD140) Induces Inflammation in Rat Right Heart Ventricle: Evidence for an Androgen-Specific, Species-Specific Mechanism, Radius Health Presentation, 2012, SUN-525.